1 Ten patients with congestive heart failure (CHF), in III and IV NYHA Class, were treated orally with a single dose of ibopamine ranging from 1.2-3.3 mg/kg, and were studied using the Swan-Ganz catheter and thermodilution technique. 2 Cardiac index (CI) and stroke volume index (SVI) were increased, and mean pulmonary pressure (PAP), systemic vascular resistances (SVR) were lowered. Ibopamine increased CI (+33%) and SVI (+26%), and decreased PAP (-17%) and SVR (-24%). All changes were statistically significant. The maximum haemodynamic effect occurred 180 min after ibopamine administration. Blood pressure and heart rate were unaffected. Tolerability was good. 3 This study shows that ibopamine when orally administered to human subjects improves cardiac performance and further investigations on its use as a therapeutic agent in the long term treatment of CHF are recommended.
Introduction
Significant improvements have been made in diuretic and vasodilator therapy of congestive heart failure (CHF) in recent years. In contrast, there has been little change in positive inotropic therapy, and cardiac glycosides remain the most commonly used oral inotropic agents. Cardiac glycosides produce only a modest enhancement of ventricular function and have a relatively low therapeutic ratio (Beller et al., 1971; Davidson & Gibson, 1973) . Thus, it is important to develop additional positive inotropic drugs.
Currently, several new positive inotropic agents, such as amrinone, and a series of oral sympathomimetic amines are under investigation (Farah & Alouisi, 1978) . Studies have also been conducted to determine whether orally active dopamine derivatives may be useful in the treatment of congestive heart failure. Dopamine (DA), however, differs from other sympathomimetic amines in that it not only increases cardiac output, but also increases renal blood flow by an action on DA receptors (Goldberg et al., 1977) . Levodopa, which is decarboxylated to DA, has been shown to shorten systolic time intervals and increase renal function in patients without heart disease and in a few patients with congestive heart failure (Duncan Finlay et al., 1971; Whitsett et al., 1972) . Levodopa, however, requires doses of 1-2 g and has a relatively short duration of action as a positive inotropic agent. In addition, the dose has to be gradually increased because of nausea, vomiting, and orthostatic hypotension.
Ibopamine, the di-isobutyric ester of epinine, has been shown in normal subjects and in patients with congestive heart failure to exert a positive inotropic effect after oral administration (Col et al., 1983; Dei Cas et al., 1980 Ladelli et al., 1983; Mengeot et al., 1981) , but some of these patients were being treated with cardiac glycosides or vasodilators (Col et al., 1983; Dei Cas et al., 1983; Mengeot et al., 1981 Mengeot et al., 1981; . The positive inotropic and diuretic effects of ibopamine in animals and in man have been reported in several publications Melloni etal., 1981; Merlo et al., 1979 Merlo et al., , 1982 Stefoni et al., 1981) .
The purpose of the present paper is to present data on the acute haemodynamic effects of ibopamine obtained from invasive studies in 10 patients with severe heart disease. Ibopamine was administered alone as single dose after discontinuation of all drugs in patients not treated with cardiac glycosides.
Methods

Patients
Ten hospitalized patients with severe congestive heart failure (CHF) were admitted to the ibopamine study after their informed consent had been obtained. Data from the patients are shown in Table 1 .
Three patients were in New York Heart Association functional class III and seven in class IV (Criteria Committee of the New York Heart Association, 1973). CHF was secondary to ischaemic cardiomyopathy (IsC) in two patients and secondary to idiopathic cardiomyopathy (IC) in eight patients; the diagnosis was based on a complete haemodynamic investigation, including left ventriculography and selective coronary arteriography.
Experimental design
The patients were studied after a stay of at least 2 days in an Intensive Care Unit. The patients were given an ordinary hospital diet with no added salt. None of the patients was being treated with cardiac glycosides. Diuretics and vasodilators were stopped at least 8 h before administration of ibopamine. 
Statistical analysis
Statistical analysis was performed by using analysis of variance according to a randomized block design and Tukey test between the basal and each subsequent mean value. Thereafter, the procedure involved a paired Student's t-test between basal values and maximum effect. A linear correlation between the maximum effect of CI, PAP, SVI, SVR and the dose of administered ibopamine was calculated.
Results
The haemodynamic values before and at the time of maximum effect produced by ibopamine Table 2 . Cardiac index increased in six and SVI in seven of the 10 patients by more than 20% and 10% respectively. The average CI and SVI increased significantly after administration of ibopamine from 2.4 to 3.21 min-' m-2 and from 30.1 to 37.8 ml/m2 respectively. The PAP and SVR were significantly decreased by ibopamine (PAP from 33.3 to 27.6 mm Hg and SVR from 1391 to 1064 dyn s cm-5). The changes in the haemodynamic values and heart rate observed at hourly intervals for 5 h are shown in Figure 1 . The average maximum effect occurred 180 min after ibopamine (Figure 1 ) and the mean values of the peak times are reported in Table 2 . Five hours after ibopamine administration all changes were still different from the basal values. The maximum effects of CI, SVI, PAP and SVR were statistically correlated to the dose of ibopamine (Figure 2 ). Ibopamine in congestive heart failure 617 Heart rate and arterial pressure were unaltered by ibopamine.
Discussion
These results show that oral administration of ibopamine 1.2-3.3 mg/kg as a single dose improves cardiac performance in patients with severe CHF. In fact, ibopamine significantly increased CI and SVI, and significantly decreased PAP and SVR. The changes were dose-related. The mean maximum haemodynamic effect occurred 180 min after oral administration and was still present at the time of the last measurement (5 h).
HR and MAP remained unchanged in accordance with previous experiments in healthy subjects and in patients with CHF (Ladelli et al., 1983; . The lack of adverse cardiac effects agrees with the studies performed with Holter monitoring in patients with angina pectoris and ventricular ectopic beats, for in these studies the number of ventricular ectopic beats remained unchanged or decreased (Montani et al., 1982) .
The haemodynamic effects of ibopamine can be explained by an action on ,-adrenergic and dopaminergic receptors. Extensive pharmacological investigations demonstrated that its activity on contractile force of the dog heart is counteracted by ,-adrenoceptor blocking agents. The effect of ibopamine to reduce renal resistance is blocked by the dopamine receptor blocking agent, (+)-sulpiride (Goldberg et al., 1979; Merlo et al., 1983) .
The cardiac and peripheral vascular activity of ibopamine is complemented by its activity on the kidney Ghirardi et al., 1980; Longhini et al., 1983; Merlo et al., 1979; Stefoni et al., 1981; . This combined action on the myocardium, after-and pre-load, tends to improve cardiac performance and the haemodynamic pattern in CHF.
These results achieved after single dose treatment are very interesting, but the therapeutic use of ibopamine in the chronic management of severe CHF needs to be clarified by further trials. The preliminary results of chronic treatment of patients with CHF are nevertheless very encouraging (Cadel et al., 1982; Nicaise et al., 1982; . If controlled evaluations confirm the efficacy and safety of ibopamine, its use in the management of CHF may represent a significant therapeutic advance.
